[18F]FDG-PET-Based Personalized Radiotherapy Dose Prescription

Johannes H. A. M. Kaanders; Johan Bussink; Erik H. J. G. Aarntzen; P. tra Braam; Heidi Rütten; Richard W. M. van der Maazen; Marcel Verheij; Sven van den Bosch

doi:10.1016/j.semradonc.2023.03.006

[18F]FDG-PET-Based Personalized Radiotherapy Dose Prescription

Johannes H. A. M. Kaanders^*, Johan Bussink, Erik H. J. G. Aarntzen, P. tra Braam, Heidi Rütten, Richard W. M. van der Maazen, Marcel Verheij, Sven van den Bosch

^*Corresponding author for this work

Research output: Contribution to journal › Review article › Academic › peer-review

Abstract

PET imaging with 2’-deoxy-2’-[18F]fluoro-D-glucose ([18F]FDG) has become one of the pillars in the management of malignant diseases. It has proven value in diagnostic workup, treatment policy, follow-up, and as prognosticator for outcome. [18F]FDG is widely available and standards have been developed for PET acquisition protocols and quantitative analyses. More recently, [18F]FDG-PET is also starting to be appreciated as a decision aid for treatment personalization. This review focuses on the potential of [18F]FDG-PET for individualized radiotherapy dose prescription. This includes dose painting, gradient dose prescription, and [18F]FDG-PET guided response-adapted dose prescription. The current status, progress, and future expectations of these developments for various tumor types are discussed.

Original language	English
Journal	Seminars in Radiation Oncology
Early online date	2023
DOIs	https://doi.org/10.1016/j.semradonc.2023.03.006
Publication status	E-pub ahead of print - 2023

Access to Document

10.1016/j.semradonc.2023.03.006

Cite this

@article{5863a387834643b4bce84a8733116d59,

title = "[18F]FDG-PET-Based Personalized Radiotherapy Dose Prescription",

abstract = "PET imaging with 2{\textquoteright}-deoxy-2{\textquoteright}-[18F]fluoro-D-glucose ([18F]FDG) has become one of the pillars in the management of malignant diseases. It has proven value in diagnostic workup, treatment policy, follow-up, and as prognosticator for outcome. [18F]FDG is widely available and standards have been developed for PET acquisition protocols and quantitative analyses. More recently, [18F]FDG-PET is also starting to be appreciated as a decision aid for treatment personalization. This review focuses on the potential of [18F]FDG-PET for individualized radiotherapy dose prescription. This includes dose painting, gradient dose prescription, and [18F]FDG-PET guided response-adapted dose prescription. The current status, progress, and future expectations of these developments for various tumor types are discussed.",

author = "Kaanders, {Johannes H. A. M.} and Johan Bussink and Aarntzen, {Erik H. J. G.} and Braam, {P. tra} and Heidi R{\"u}tten and {van der Maazen}, {Richard W. M.} and Marcel Verheij and {van den Bosch}, Sven",

note = "Funding Information: No funding was received for this study. Publisher Copyright: {\textcopyright} 2023 The Author(s)",

year = "2023",

doi = "10.1016/j.semradonc.2023.03.006",

language = "English",

journal = "Seminars in Radiation Oncology",

issn = "1053-4296",

}

TY - JOUR

T1 - [18F]FDG-PET-Based Personalized Radiotherapy Dose Prescription

AU - Kaanders, Johannes H. A. M.

AU - Bussink, Johan

AU - Aarntzen, Erik H. J. G.

AU - Braam, P. tra

AU - Rütten, Heidi

AU - van der Maazen, Richard W. M.

AU - Verheij, Marcel

AU - van den Bosch, Sven

PY - 2023

Y1 - 2023

N2 - PET imaging with 2’-deoxy-2’-[18F]fluoro-D-glucose ([18F]FDG) has become one of the pillars in the management of malignant diseases. It has proven value in diagnostic workup, treatment policy, follow-up, and as prognosticator for outcome. [18F]FDG is widely available and standards have been developed for PET acquisition protocols and quantitative analyses. More recently, [18F]FDG-PET is also starting to be appreciated as a decision aid for treatment personalization. This review focuses on the potential of [18F]FDG-PET for individualized radiotherapy dose prescription. This includes dose painting, gradient dose prescription, and [18F]FDG-PET guided response-adapted dose prescription. The current status, progress, and future expectations of these developments for various tumor types are discussed.

AB - PET imaging with 2’-deoxy-2’-[18F]fluoro-D-glucose ([18F]FDG) has become one of the pillars in the management of malignant diseases. It has proven value in diagnostic workup, treatment policy, follow-up, and as prognosticator for outcome. [18F]FDG is widely available and standards have been developed for PET acquisition protocols and quantitative analyses. More recently, [18F]FDG-PET is also starting to be appreciated as a decision aid for treatment personalization. This review focuses on the potential of [18F]FDG-PET for individualized radiotherapy dose prescription. This includes dose painting, gradient dose prescription, and [18F]FDG-PET guided response-adapted dose prescription. The current status, progress, and future expectations of these developments for various tumor types are discussed.

UR - http://www.scopus.com/inward/record.url?scp=85153614018&partnerID=8YFLogxK

U2 - 10.1016/j.semradonc.2023.03.006

DO - 10.1016/j.semradonc.2023.03.006

M3 - Review article

SN - 1053-4296

JO - Seminars in Radiation Oncology

JF - Seminars in Radiation Oncology

ER -

[18F]FDG-PET-Based Personalized Radiotherapy Dose Prescription

Abstract

Access to Document

Other files and links

Cite this